Guggenheim Upgrades Merus Labs International (TSE:MSL) to “Strong-Buy”

Merus Labs International (TSE:MSL) (NASDAQ:MSLI) was upgraded by equities researchers at Guggenheim to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Several other brokerages also recently issued reports on MSL. Leerink Partners raised shares of Merus Labs International to a “strong-buy” rating in a report on Monday, April 6th. Cantor Fitzgerald raised shares of Merus Labs International to a “strong-buy” rating in a report on Wednesday, March 11th. Three equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, Merus Labs International has an average rating of “Strong Buy”.

Merus Labs International Stock Performance

Merus Labs International has a 1 year low of C$0.95 and a 1 year high of C$1.76.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.